Please login to the form below

Not currently logged in
Email:
Password:

Increlex

This page shows the latest Increlex news and features for those working in and with pharma, biotech and healthcare.

EMA publishes European drug shortage details

EMA publishes European drug shortage details

First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... The two other drugs with shortages assessed by the EMA are Ipsen's Increlex (mecasermin), for people with a growth disorder due to severe primary insulin-like growth

Latest news

  • North-South divide?

    As such, treatments for high need, orphan conditions have been approved with costs per QALY potentially above £40, 000 (46, 000), like mecasermin (Increlex) for growth failure in children and nelarabine

  • Reaching new heights

    A compelling video illustrated the case of the first UK patient diagnosed with Severe Primary IGFD and treated with Recombinant human insulin-like growth factor-I (rhIGF-I), Increlex. ... 75 per cent were 'considerably more confident' in using rhIGF-1

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics